logo/base Created with Sketch.
Contact us

FibroScan® GO

The state-of-the-art non-invasive solution for liver disease management, affordable to all.

Powered by LSM by VCTE® and CAP for liver fibrosis and steatosis management.

chevron chevron

A small and compact device for easy integration

FibroScan® GO is a point-of-care solution for primary care office-based settings only

Pay-per-exam Solution

Full ecosystem of solutions, including service coverage and support

Cloud-based Solution

Centralized data management and user-friendly interface

All Patient Morphologies

Can be used with all probes S+, M+ and XL+

Renowned & Endorsed

Supported by 6,270+ peer reviewed publications and 250+ international guidelines

Enhanced care for your patients

Simple, fast assessment of your patients’ liver health.

Innovative technology offers simplified exams on all morphologies.

Immediate results for informative and straightforward provider/patient consultations.

Identify, assess and monitor patients at risk for liver disease right in your office.

Watch how the FibroScan exam works

A cloud-based solution offering you everyday support

 

Automatically transfer of FibroScan® results to the LHM™ platform to help you make data-driven decisions.

 

Access historical patient data and generate reports easily shared with patients and referring physicians.

 

Enhance examinations with FibroScan®-based Scores and interpretation tools.

 

Monitor and manage your patients’ liver disease with patient history and clinical care pathway tools directly in the LHM™ platform.

Learn more

A state-of-the-art FibroScan®

Quickly and easily assess liver fibrosis with LSM by VCTE® and steatosis with CAP.1,2,3

Learn more

Additional resources to support the management of liver health

  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron
  • FibroScan® probes

    VCTE® probe

    Optimize measurement accuracy on all patients of varying size

    chevron
  • FibroScan® Mini+ 430

    FibroScan® by echosens

    The non-invasive solution for comprehensive management of liver health

    chevron

Proven & Trusted

The fact that I now have FibroScan, and can provide an accurate, non-invasive test that can be performed in the clinic in minutes and produce immediate, visual results is a game-changer.

Dr. Radhika Vayani

Primary Care Physician

For my practice, there is no doubt: integrating FibroScan helps me catch disease earlier, empowers strategic intervention, and puts more patients on the path to better health.

Dr. Jinsong Zhang

Primary Care Physician

More testimonials chevron

Request a demo!

Interested in FibroScan®?

Contact us

Equipment compatible with an S+ probe (sold separately).

The FibroScan® 230 is intended to measure liver stiffness (E) using Vibration Controlled Transient Elastography (VCTE®) at 50 Hz shear wave frequency and liver ultrasound attenuation (CAP)* at 3.5 MHz. FibroScan liver stiffness measurements (LSM) by VCTE® may aid the physician in determining the likelihood of cirrhosis and may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of liver fibrosis. FibroScan CAP measurements may be used, taken in context with other clinical and laboratory data, as an aid in the assessment of hepatic steatosis. FibroScan® is indicated as a non-invasive aid to clinical management diagnosis and monitoring of adult and pediatric patients with confirmed or suspected liver disease, as part of an overall assessment of the liver. Results in the pediatric population should be interpreted while considering the clinical condition and the overall patient profile. The FibroScan® device is intended for use by healthcare professionals in hospitals, clinics or any facility where healthcare is provided.
*CAP refers to ultrasound attenuation coefficient (originally defined as Controlled Attenuation Parameter).

All personal and health data generated by the FibroScan® GO solution is managed in compliance with HIPAA regulations. Data located on Echosens Cloud is managed by an ISO27001 certified organization.

1. Wong VW, et al. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478.

2. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.

3. Steadman R, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-158.

chevron User Guides FibroScan 230